MUTATION_ID,VIRUS,GENOTYPE,GENE,AA,GCV,CDV,FOS,BCV,Letermovir,Tomeglovir,GW275175,Maribavir,Cyclopropavir,REF_REV,REF_TITLE,REF_LINK,REF_DOI,TM,TM_GROUP,TM_CLASS,"test-type***[in vitro, hypothesised, clinical isolate, in silico prediction]",co-gene,co-AA,Created_date,Created_by,note,Status,,,,,,,
65,HCMV,TOWNE,UL54,D301N,2.6,3,0.5,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus,https://academic.oup.com/jid/article/188/1/32/821141,https://doi.org/10.1086/375743,"Marker transfer, plaque reduction assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
,,AD169,UL54,C304S,1.3,1.4,1.1,,,,,,,,Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/,doi: 10.1016/j.jcv.2011.01.004,"BAC recombinant, SEAP",in vitro,strong,Tested,,,,,,,,,,,,,
66,HCMV,TOWNE,UL54,N408D,4.9,5.6,1.3,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,"Cotransfection of overlapp, plaque reduction assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
67,AD169,AD169,UL54,N408K,4.2,21,0.7,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.,https://europepmc.org/article/pmc/pmc1797699,DOI: 10.1128/AAC.00633-06,"Marker transfer, SEAP assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
68,HCMV,AD169,UL54,N408S,3.1,7.5,1,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,"Novel DNA polymerase mutations conferring cytomegalovirus
resistance: Input of BAC-recombinant phenotyping and 3D model",https://www.sciencedirect.com/science/article/abs/pii/S0166354213000259?via%3Dihub,https://doi.org/10.1016/j.antiviral.2013.02.002,"BAC recombinant, PRA",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
69,HCMV,TOWNE,UL54,N410K,2.9,3,0.8,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus,https://academic.oup.com/jid/article/188/1/32/821141,https://doi.org/10.1086/375743,"Marker transfer, plaque reduction assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
70,HCMV,TOWNE,UL54,F412C,4.2,18,1.2,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,"Cotransfection of overlapp, plaque reduction assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
71,HCMV,AD169,UL54,F412L,4.6,9.4,1.1,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/,doi: 10.1016/j.jcv.2011.01.004,"BAC recombinant, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
72,HCMV,AD169,UL54,F412S,5.3,13,0.8,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/,doi: 10.1016/j.jcv.2011.01.004,"BAC recombinant, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
73,HCMV,TOWNE,UL54,F412V,4.3,15.5,1.1,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,"Cotransfection of overlapp, plaque reduction assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
74,HCMV,MERLIN,UL54,D413A,6.5,11,0.8,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,"[51,82]",,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
75,HCMV,TOWNE,UL54,D413E,4.8,4.3,0.8,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus,https://academic.oup.com/jid/article/188/1/32/821141,https://doi.org/10.1086/375743,"Marker transfer, plaque reduction assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
76,HCMV,AD169,UL54,D413N,3.8,10,1,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/,doi: 10.1128/AAC.03214-14,"BAC recombinant, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
77,HCMV,Susceptable Clinical Isolate,UL54,P488R,3.5,7.9,0.6,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,"Recombinant BAC, PRA",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
78,HCMV,MERLIN,UL54,N495K,1.1,1.1,3.4,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet,Antiviral Therapy 2006;,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
79,HCMV,AD169,UL54,K500N,3.2,3,1.2,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,11: 537–540.,,"Recombinant BAC, PRA",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
80,HCMV,TOWNE,UL54,L501I,6,9.1,1.4,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,"Cotransfection of overlapp, plaque reduction assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
81,HCMV,TOWNE,UL54,T503I,2.9,6.1,0.5,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus,https://academic.oup.com/jid/article/188/1/32/821141,https://doi.org/10.1086/375743,"Marker transfer, plaque reduction assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
review reference wrong,HCMV,MERLIN,UL54,A505V,1.8,2,1.1,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,125,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
83,HCMV,TOWNE,UL54,K513E,5,9.1,1.4,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,"Cotransfection of overlapp, plaque reduction assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
84,HCMV,MERLIN,UL54,K513N,6,12.5,1.5,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selected in Vitro by Cidofovir Confers a Slow Replication Phenotype in Cell Culture,https://www.sciencedirect.com/science/article/pii/S0042682298992996,https://doi.org/10.1006/viro.1998.9299,"Marker Transfer, Plaque Reduction Assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
84,HCMV,MERLIN,UL54,K513N,9.8,34,3,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selected in Vitro by Cidofovir Confers a Slow Replication Phenotype in Cell Culture,https://www.sciencedirect.com/science/article/pii/S0042682298992996,https://doi.org/10.1006/viro.1998.9299,"Marker Transfer, Plaque Reduction Assay",in vitro,strong,Tested,UL54,V812L,17/11/2019,OJCharles,,,,,,,,,
85,HCMV,AD169,UL54,K513R,3.7,10,1.1,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/,doi: 10.1128/AAC.03214-14,"BAC recombinant, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
86,HCMV,MERLIN,UL54,D515E,2.7,,4.6,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,[70],,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
,HCMV,TOWNE,UL54,D515G,1,1,1.2,,,,,,,,Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus,https://academic.oup.com/jid/article/188/1/32/821141,https://doi.org/10.1086/375743,"Marker transfer, plaque reduction assay",in vitro,strong,Tested,,,,,,,,,,,,,
87,HCMV,MERLIN,UL54,D515Y,5.6,,4.6,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,[79],,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
88,HCMV,TOWNE,UL54,L516R,2.1,5.1,0.8,,,,,,,Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus,https://academic.oup.com/jid/article/188/1/32/821141,https://doi.org/10.1086/375743,"Marker transfer, plaque reduction assay",in vitro,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
89,HCMV,MERLIN,UL54,I521T,2.1,5.1,0.8,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,"[51,70,127]",,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
,,AD169,UL54,I521T,3,3.9,1,,,,,,,,Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus,http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf,doi:10.1016/j.jcv.2008.04.005.,"Marker Transfer , SEAP",in vitro,strong,Tested,,,,,,,,,,,,,
90,HCMV,AD169,UL54,P522A,3,4.1,1,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus,http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf,doi:10.1016/j.jcv.2008.04.005.,"Marker Transfer , SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
,,AD169,UL54,P522L,1.3,1.2,1.4,,,,,,,,Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus,http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf,doi:10.1016/j.jcv.2008.04.005.,"Marker Transfer , SEAP",in vitro,strong,Tested,,,,,,,,,,,,,
91,HCMV,TOWNE,UL54,P522S,3.1,3.6,1.1,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,"Cotransfection of overlapp, plaque reduction assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
92,HCMV,AD169,UL54,524del,3.5,9.7,1.1,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,"Novel DNA polymerase mutations conferring cytomegalovirus
resistance: Input of BAC-recombinant phenotyping and 3D model",https://www.sciencedirect.com/science/article/abs/pii/S0166354213000259?via%3Dihub,https://doi.org/10.1016/j.antiviral.2013.02.002,"BAC recombinant, PRA",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
93,HCMV,MERLIN,UL54,V526L,5.5,2.5,1.8,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,[98],,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
94,HCMV,AD169,UL54,C539G,3.1,4.4,1,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/,doi: 10.1128/AAC.03214-14,"BAC recombinant, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
95,HCMV,Susceptable Clinical Isolate,UL54,C539R,3.2,13.3,0.7,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,"Recombinant BAC, PRA",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
96,HCMV,MERLIN,UL54,D542E,1.5,12,1.7,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,[129],,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
,,AD169,UL54,V544A,1,1.1,0.9,,,,,,,,Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/,doi: 10.1016/j.jcv.2011.01.004,"BAC recombinant, SEAP",in vitro,strong,Tested,,,,,,,,,,,,,
97,HCMV,TOWNE,UL54,L545S,3.5,9.1,1.2,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,"Cotransfection of overlapp, plaque reduction assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
98,HCMV,AD169,UL54,L545W,4.9,6.3,1.3,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/,doi: 10.1016/j.jcv.2011.01.004,"BAC recombinant, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
99,HCMV,AD169,UL54,T552N,1.9,1.2,2.6,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,"Recombinant BAC, PRA",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
100,HCMV,AD169,UL54,Q578H,3.3,2.3,4.5,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/,doi: 10.1016/j.jcv.2011.01.004,"BAC recombinant, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
102,HCMV,AD169,UL54,S585A,1.5,1.4,2.7,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,"Recombinant BAC, PRA",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
103,HCMV,TOWNE,UL54,D588E,1.3,1.1,2.3,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,"Cotransfection of overlapp, plaque reduction assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
,,AD169,UL54,D588N,2,1.3,2.8,,,,,,,,Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/,doi: 10.1016/j.jcv.2011.01.004,"BAC recombinant, SEAP",in vitro,strong,Tested,,,,,,,,,,,,,
104,HCMV,MERLIN,UL54,D588N,3.8,2.7,"3.2,9",,,,,,,Rev. Med. Virol. 2016; 26: 161–182,"[51,67,72,83,122]",,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
105,HCMV,Susceptable Clinical Isolate,UL54,F595I,1.3,1.2,2,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,"Recombinant BAC, PRA",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
,HCMV,TOWNE,UL54,A692S,1.6,1.7,3.3,,,,,,,,Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus,https://academic.oup.com/jid/article/188/1/32/821141,https://doi.org/10.1086/375743,"Marker transfer, plaque reduction assay",in vitro,strong,Tested,,,,,,,,,,,,,
106,HCMV,MERLIN,UL54,T700A,1.2,1.3,5.8,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,"Cotransfection of overlapp, plaque reduction assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
folloup values in review paper,HCMV,MERLIN,UL54,T700A,0.9,1.5,4.7,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,"[51,54,69,78,118]",,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,U,,,,,,,
,HCMV,AD169,UL54,A714V,0.8,0.7,0.8,,,,,,,,Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/,doi: 10.1016/j.jcv.2011.01.004,"BAC recombinant, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
107,HCMV,MERLIN,UL54,V715M,1.3,1.1,9.5,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,"Cotransfection of overlapp, plaque reduction assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
folloup values in review paper,HCMV,MERLIN,UL54,V715M,1,1.1,5.5,,,,,,,Rev. Med. Virol. 2016; 26: 161–182, ,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,U,,,,,,,
109,HCMV,AD169,UL54,I726V,1.9,1.9,1.2,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
110,HCMV,TOWNE,UL54,E756D,1.2,0.7,3.4,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus,https://academic.oup.com/jid/article/188/1/32/821141,https://doi.org/10.1086/375743,"Marker transfer, plaque reduction assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
review wrong ref & value,HCMV,TOWNE,UL54,E756K,3.5,2.2,>8,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus,https://academic.oup.com/jid/article/188/1/32/821141,https://doi.org/10.1086/375743,"Marker transfer, plaque reduction assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
112,HCMV,MERLIN,UL54,E756Q,1.7,1,4.3,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,[128],,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
113,HCMV,AD169,UL54,L773V,3,2.5,4.4,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/,doi: 10.1128/AAC.03214-14,"BAC recombinant, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
114,HCMV,MERLIN,UL54,L776M,2.5,1,3.5,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,"[51,133]",,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
115,HCMV,TOWNE,UL54,V781I,1,1.2,5.2,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,"Cotransfection of overlapp, plaque reduction assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
116,HCMV,MERLIN,UL54,V787A,2.5,,3.5,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,[92],,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
117,HCMV,MERLIN,UL54,V787L,2.4,1,4.1,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,"[80,119,128]",,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
118,HCMV,TOWNE,UL54,L802M,1.1,0.9,3.2,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,"Cotransfection of overlapp, plaque reduction assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
119,HCMV,AD169,UL54,L802V,1.8,1.1,0.9,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,"Recombinant BAC, PRA",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
120,HCMV,TOWNE,UL54,K805Q,1,2.2,0.18,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,"Cotransfection of overlapp, plaque reduction assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
121,HCMV,MERLIN,UL54,A809V,2.6,1.7,6.3,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,"[65,90,123]",,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
,,AD169,UL54,A809V,,,3.6,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
122,HCMV,MERLIN,UL54,V812L,2.5,3.2,2.9,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,"[83,119,126]",,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
123,HCMV,MERLIN,UL54,T813S,2.5,2.7,4.9,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,[90],,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
124,HCMV,TOWNE,UL54,T821I,4.5,1.9,21,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,"Cotransfection of overlapp, plaque reduction assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
125,HCMV,MERLIN,UL54,P829S,2,1.6,1.1,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,"[49,119]",,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
126,HCMV,AD169,UL54,A834P,5.4,3,6.4,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.,https://europepmc.org/article/pmc/pmc1797699,DOI: 10.1128/AAC.00633-06,"Marker transfer, SEAP assay",in vitro,strong,Tested,,,,OJCharles,,,,,,,,,
126,HCMV,AD169,UL54,A834P,22.7,18.8,7.2,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.,https://europepmc.org/article/pmc/pmc1797699,DOI: 10.1128/AAC.00633-06,"Marker transfer, SEAP assay",in vitro,strong,Tested,UL54,N408K,17/11/2019,OJCharles,,,,,,,,,
127,HCMV,MERLIN,UL54,T838A,1.8,0.8,2.4,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,[83],,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
128,HCMV,MERLIN,UL54,G841A,3.2,2.6,4.3,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,"[72,78,90]",,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
130,HCMV,MERLIN,UL54,M844T,1.4,1.3,2.5,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,[135],,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
131,HCMV,MERLIN,UL54,M844V,2.5,1.6,2.2,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,[135],,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
132,HCMV,Susceptable Clinical Isolate,UL54,L862F,1.7,0.9,1.1,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,"Recombinant BAC, PRA",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
133,HCMV,Susceptable Clinical Isolate,UL54,V946L,1.1,0.9,2.4,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,"Recombinant BAC, PRA",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
134,HCMV,AD169,UL54,L957F,2.7,1.4,1.3,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,"Recombinant BAC, PRA",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
,HCMV,TOWNE,UL54,G971D,1.4,1,1.2,,,,,,,,Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus,https://academic.oup.com/jid/article/188/1/32/821141,https://doi.org/10.1086/375743,"Marker transfer, plaque reduction assay",in vitro,strong,Tested,,,,,,,,,,,,,
135,HCMV,MERLIN,UL54,del981-2,8.3,2.8,3.6,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,"[76,97,117,123]",,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
,,AD169,UL54,A987G,5.1,4.5,,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
136,HCMV,TOWNE,UL54,A987G,5.3,11.3,1.2,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,"Cotransfection of overlapp, plaque reduction assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
,HCMV,TOWNE,UL54,S676G,1.1,1.2,0.9,,,,,,,,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,"Cotransfection of overlapp, plaque reduction assay",in vitro,strong,Tested,,,16/03/2020,OJCharles,,,,,,,,,
,HCMV,TOWNE,UL54,V759M,1.5,1.1,1.1,,,,,,,,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,"Cotransfection of overlapp, plaque reduction assay",in vitro,strong,Tested,,,16/03/2020,OJCharles,,,,,,,,,
,HCMV,TOWNE,UL54,F412C,6.2,16,3.1,,,,,,,,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,"Cotransfection of overlapp, plaque reduction assay",in vitro,strong,Tested,UL54,L802M,16/03/2020,OJCharles,,,,,,,,,
,HCMV,TOWNE,UL54,K513E,6.6,11.1,2.7,,,,,,,,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,"Cotransfection of overlapp, plaque reduction assay",in vitro,strong,Tested,UL54,D558E,,,,,,,,,,,
,HCMV,TOWNE,UL54,K805Q,4.3,2.1,10.1,,,,,,,,Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/,,"Cotransfection of overlapp, plaque reduction assay",in vitro,strong,Tested,UL54,T821I,,,,,,,,,,,
,HCMV,AD169,UL54,L545S,5,11.9,1,,,,,,,,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,HCMV,AD169,UL54,V812L,2.6,2,0.8,,,,,,,,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,HCMV,AD169,UL54,879G,1.2,0.9,0.9,,,,,,,,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,HCMV,AD169,UL54,L545S,7.3,4.5,1.8,,,,,,,,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,"Recombinant BAC, PRA",in vitro,strong,Tested,UL54,P829S,,,,,,,,,,,
,HCMV,AD169,UL54,N408D,4,4.2,1.3,,,,,,,,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,HCMV,AD169,UL54,N408D,4.2,1.9,4,,,,,,,,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,"Recombinant BAC, PRA",in vitro,strong,Tested,UL54,T552N,,,,,,,,,,,
,HCMV,AD169,UL54,N408D,4.9,4.5,3.3,,,,,,,,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,"Recombinant BAC, PRA",in vitro,strong,Tested,UL54,L957F,,,,,,,,,,,
,HCMV,AD169,UL54,T552N,1.6,0.9,5.5,,,,,,,,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,"Recombinant BAC, PRA",in vitro,strong,Tested,UL54,L957F,,,,,,,,,,,
,HCMV,AD169,UL54,757K,1.3,0.8,1.3,,,,,,,,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,HCMV,AD169,UL54,L802M,1.7,1,2.7,,,,,,,,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,HCMV,AD169,UL54,926V,1.3,1.1,0.9,,,,,,,,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,HCMV,AD169,UL54,K500N,2.4,2.4,2.7,,,,,,,,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,"Recombinant BAC, PRA",in vitro,strong,Tested,UL54,S585A,,,,,,,,,,,
,HCMV,Susceptable Clinical Isolate,UL54,V787L,1.8,0.9,2.4,,,,,,,,Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/,,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,HCMV,AD169,UL97,del590-593,4.8,1,,,,,,,,,New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/,,"Lab-drived mutant, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,HCMV,AD169,UL54,L545S,7.4,16,1.5,,,,,,,,New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/,,"Lab-drived mutant, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,HCMV,AD169,UL54,L545S,16,6.5,1.3,,,,,,,,New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/,,"Lab-drived mutant, PRA",in vitro,strong,Tested,UL97,M460I,,,,,,,,,,,
,HCMV,AD169,UL54,T552N,3.2,2.1,5.8,,,,,,,,New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/,,"Lab-drived mutant, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,HCMV,TOWNE,UL54,L737M,1.1,2,1,,,,,,,,Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.,https://europepmc.org/article/pmc/pmc1797699,DOI: 10.1128/AAC.00633-06,"Marker transfer, Plaque Reduction Assay",in vitro,strong,Tested,,,,,,,,,,,,,
,HCMV,TOWNE,UL54,A834P,6.1,6,7.7,,,,,,,,Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.,https://europepmc.org/article/pmc/pmc1797699,DOI: 10.1128/AAC.00633-06,"Marker transfer, Plaque Reduction Assay",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,Q229K,1.2,1,1.2,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,D247N,0.9,0.9,1.3,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,D262N,1.1,1,1.2,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,T271A,1,0.7,0.9,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,V284E,1.2,1.1,1.2,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,D288N,1.2,1.2,1.2,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,F396L,1.4,0.9,0.9,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,L424V,1.3,1.3,1.2,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,T437M,1,1,0.8,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,F460L,1.2,1.2,1.2,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,A505V,1.9,1.9,1,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,A543S,1,1,1,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,S612N,0.9,1,0.7,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,V654G,1.1,1.1,1.1,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,S660G,1,0.9,1.1,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,S660N,1.2,1,0.8,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,G667N,0.9,0.8,1,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,A692G,0.8,0.9,1,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,I726T,2,1.7,1.1,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,E793V,0.9,0.7,1.1,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,Q795P,0.9,0.9,1.1,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,Q795R,1,0.9,1,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,G841S,2.2,1.1,2.1,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,P859A,0.8,1,0.8,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,V902G,1.2,1,1,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,E903G,1.1,1,0.9,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,K947E,1,1,1.1,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,M959T,1.2,0.9,1.2,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,N345S,1.2,0.7,0.9,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,V467G,0.9,0.8,0.4,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,Q578L,1.9,0.8,3,,,,,,,,"Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/,doi: 10.1093/infdis/jit654,"Recombinant BAC, PRA",in vitro,strong,Tested,,,,,,,,,,,,,
relook,,MERLIN,UL97,L595T,2 - 4,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,NA,NA,NA,Tested,,,17/11/2019,OJCharles,review has no reference or data for mention,,,,,,,,
relook,HCMV,MERLIN,UL97,D605E,r,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,Clinical Isolate,Potential,weak,Hypothesised,,,17/11/2019,OJCharles,,,,,,,,,
18,HCMV,MERLIN,UL97,F342S,7.8,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
19,HCMV,MERLIN,UL97,del355,16,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
20,HCMV,MERLIN,UL97,V356G,5.5,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
21,HCMV,MERLIN,UL97,L405P,2.5,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
22,HCMV,MERLIN,UL97,D456N,12,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
23,HCMV,MERLIN,UL97,M460I,5,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
24,HCMV,MERLIN,UL97,M460T,9.3,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
25,HCMV,MERLIN,UL97,M460V,8.3,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
26,HCMV,MERLIN,UL97,V466G,3.5,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
27,HCMV,MERLIN,UL97,C480R,9,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
28,HCMV,MERLIN,UL97,C518Y,12,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
29,HCMV,MERLIN,UL97,H520Q,10,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
30,HCMV,MERLIN,UL97,P521L,17,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
31,HCMV,MERLIN,UL97,del591-594,6,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
32,HCMV,MERLIN,UL97,del590-600,6.3,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
33,HCMV,MERLIN,UL97,del590-603,,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
34,HCMV,MERLIN,UL97,A591V,1.3,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
35,HCMV,MERLIN,UL97,del591-607,6.2,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
36,HCMV,MERLIN,UL97,C592F,31.5,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
37,HCMV,MERLIN,UL97,C592G,2.9,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
38,HCMV,MERLIN,UL97,A594E,3,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
39,HCMV,MERLIN,UL97,A594G,13.5,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
40,HCMV,MERLIN,UL97,A594P,2.9,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
41,HCMV,MERLIN,UL97,A594T,2.7,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
42,HCMV,MERLIN,UL97,A594V,8.3,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
43,HCMV,MERLIN,UL97,L595F,15.7,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
44,HCMV,MERLIN,UL97,L595S,9.2,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
45,HCMV,MERLIN,UL97,L595W,5.1,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
46,HCMV,MERLIN,UL97,del595,13.3,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
47,HCMV,MERLIN,UL97,del595-603,8.4,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
48,HCMV,MERLIN,UL97,del596,,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
49,HCMV,MERLIN,UL97,E596G,2.3,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
50,HCMV,MERLIN,UL97,E596Y*,6.4,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
51,HCMV,MERLIN,UL97,G598S,,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
52,HCMV,MERLIN,UL97,K599E,,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
53,HCMV,MERLIN,UL97,K599T,5.3,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
54,HCMV,MERLIN,UL97,del600,1.9,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
55,HCMV,MERLIN,UL97,del601-603,11,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
56,HCMV,MERLIN,UL97,C603R,3.6-8.3,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
57,HCMV,MERLIN,UL97,C603S,1.9,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
58,HCMV,MERLIN,UL97,C603W,8,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
59,HCMV,MERLIN,UL97,C607F,1.9,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
60,HCMV,MERLIN,UL97,C607Y*,12.5,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
61,HCMV,MERLIN,UL97,I610T,2.8,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
62,HCMV,MERLIN,UL97,A613V,2.3,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
63,HCMV,MERLIN,UL97,del617,10,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
64,HCMV,MERLIN,UL97,E655K,1.7,,,,,,,,,Rev. Med. Virol. 2016; 26: 161–182,,,,,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
137,HCMV,AD169,UL89,D344E,,,,,1.8,1.7,9.4,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-17,"https://doi.org/10
.1128/AAC.01325-17","Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
138,HCMV,AD169,UL89,C347S,,,,,0.6,0.3,27,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-18,"https://doi.org/10
.1128/AAC.01325-18","Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
139,HCMV,AD169,UL89,R351H,,,,,0.7,0.4,8.5,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-19,"https://doi.org/10
.1128/AAC.01325-19","Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
140,HCMV,AD169,UL56,E769D,,,,,1,0.8,0.7,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-20,"https://doi.org/10
.1128/AAC.01325-20","Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
141,HCMV,AD169,UL56,Q204R,,,,,1.5,2.7,4.2,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-21,"https://doi.org/10
.1128/AAC.01325-21","Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
142,HCMV,AD169,UL56,Q204R,,,,,2.5,5.8,21,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-22,"https://doi.org/10
.1128/AAC.01325-22","Recombinant BAC, SEAP",in vitro,strong,Tested,UL89,D344E,17/11/2019,OJCharles,,,,,,,,,
143,HCMV,AD169,UL56,N232Y,,,,,17,2.7,0.8,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-23,"https://doi.org/10
.1128/AAC.01325-23","Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
144,HCMV,AD169,UL56,K258E,,,,,14,0.3,0.7,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-24,"https://doi.org/10
.1128/AAC.01325-24","Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
145,HCMV,AD169,UL56,F261L,,,,,2.5,1,0.7,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-25,"https://doi.org/10
.1128/AAC.01325-25","Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
146,HCMV,AD169,UL56,F261L,,,,,4.8,2.1,10,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-26,"https://doi.org/10
.1128/AAC.01325-26","Recombinant BAC, SEAP",in vitro,strong,Tested,UL89,D344E,17/11/2019,OJCharles,,,,,,,,,
147,HCMV,AD169,UL56,M329T,,,,,4.5,1.1,0.8,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-27,"https://doi.org/10
.1128/AAC.01325-27","Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
148,HCMV,AD169,UL56,M329T,,,,,8,2.2,10,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-28,"https://doi.org/10
.1128/AAC.01325-28","Recombinant BAC, SEAP",in vitro,strong,Tested,UL89,D344E,17/11/2019,OJCharles,,,,,,,,,
149,HCMV,AD169,UL56,E237D,,,,,16,0.3,0.5,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-29,"https://doi.org/10
.1128/AAC.01325-29","Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
150,HCMV,AD169,UL56,E237D,,,,,34,0.6,7.4,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-30,"https://doi.org/10
.1128/AAC.01325-30","Recombinant BAC, SEAP",in vitro,strong,Tested,UL89,D344E,17/11/2019,OJCharles,,,,,,,,,
151,HCMV,AD169,UL89,N320H,,,,,1.8,6.5,4.2,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-31,"https://doi.org/10
.1128/AAC.01325-31","Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
152,HCMV,AD169,UL89,M359I,,,,,1.5,7.4,0.5,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-32,"https://doi.org/10
.1128/AAC.01325-32","Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
153,HCMV,AD169,UL89,I334V,,,,,1.1,0.9,0.9,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-33,"https://doi.org/10
.1128/AAC.01325-33","Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
154,HCMV,AD169,UL89,N329S,,,,,2,15,0.7,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-34,"https://doi.org/10
.1128/AAC.01325-34","Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
155,HCMV,AD169,UL89,T350M,,,,,2.8,8.7,5.1,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-35,"https://doi.org/10
.1128/AAC.01325-35","Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
156,HCMV,AD169,UL89,V362M,,,,,1.2,98,0.6,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-36,"https://doi.org/10
.1128/AAC.01325-36","Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
157,HCMV,AD169,UL89,H389N,,,,,1.1,29,0.9,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-37,"https://doi.org/10
.1128/AAC.01325-37","Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
158,HCMV,AD169,UL89,N405D,,,,,1,15,0.7,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-38,"https://doi.org/10
.1128/AAC.01325-38","Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
159,HCMV,AD169,UL89,I334V,,,,,1.2,12,0.6,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-39,"https://doi.org/10
.1128/AAC.01325-39","Recombinant BAC, SEAP",in vitro,strong,Tested,UL89,N405D,17/11/2019,OJCharles,,,,,,,,,
160,HCMV,AD169,UL56,L208M,,,,,0.8,3.4,0.7,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-40,"https://doi.org/10
.1128/AAC.01325-40","Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
161,HCMV,AD169,UL56,E407D,,,,,1.3,6,0.9,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-41,"https://doi.org/10
.1128/AAC.01325-41","Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
162,HCMV,AD169,UL56,H637Q,,,,,0.9,2,0.9,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-42,"https://doi.org/10
.1128/AAC.01325-42","Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
163,HCMV,AD169,UL56,V639M,,,,,1,10,0.9,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-43,"https://doi.org/10
.1128/AAC.01325-43","Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
164,HCMV,AD169,UL56,H637Q,,,,,1.2,17,0.8,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-44,"https://doi.org/10
.1128/AAC.01325-44","Recombinant BAC, SEAP",in vitro,strong,Tested,UL56,V639M,17/11/2019,OJCharles,,,,,,,,,
165,HCMV,AD169,UL56,L764M,,,,,1.1,0.4,1,,,,Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds,https://aac.asm.org/content/61/11/e01325-45,"https://doi.org/10
.1128/AAC.01325-45","Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
,,AD169,UL54,del981-982,7.3,3.8,3.1,,,,,,,,"New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir",https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf,"https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP",in vitro,strong,Tested,,,,,,,,,,,,,
166,HCMV,AD169,UL56,C25F,,,,,5.4,,,,,Antiviral Research 163 (2019) 91–105,"New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir",https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf,"https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
,HCMV,AD169,UL56,L51M,,,,,0.8,,,,,,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,,,,,,,,,,,
167,HCMV,AD169,UL56,S229F,,,,,1.8,,,,,Antiviral Research 163 (2019) 91–106,A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance,https://www.sciencedirect.com/science/article/pii/S0166354217306393,https://doi.org/10.1016/j.antiviral.2017.10.019,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
168,HCMV,AD169,UL56,V231A,,,,,2.1,,,,,Antiviral Research 163 (2019) 91–107,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
many,HCMV,AD169,UL56,V231L,,,,,5.1,,,,,Antiviral Research 163 (2019) 91–108,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
170,HCMV,MERLIN,UL56,N232Y,,,,,17,,,,,Antiviral Research 163 (2019) 91–109,Chou (2017a),,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
171,HCMV,AD169,UL56,V236A,,,,,2.9,,,,,Antiviral Research 163 (2019) 91–110,"New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir",https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf,"https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
172,HCMV,AD169,UL56,V236L,,,,,14,,,,,Antiviral Research 163 (2019) 91–111,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
many,HCMV,AD169,UL56,V236M,,,,,32,,,,,Antiviral Research 163 (2019) 91–112,A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance,https://www.sciencedirect.com/science/article/pii/S0166354217306393,https://doi.org/10.1016/j.antiviral.2017.10.019,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
174,HCMV,AD169,UL56,E237D,,,,,10,,,,,Antiviral Research 163 (2019) 91–113,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
175,HCMV,AD169,UL56,L241P,,,,,96,,,,,Antiviral Research 163 (2019) 91–114,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
176,HCMV,AD169,UL56,T244K,,,,,3.3,,,,,Antiviral Research 163 (2019) 91–115,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
177,HCMV,MERLIN,UL56,L254F,,,,,3.2,,,,,Antiviral Research 163 (2019) 91–116,Chou (2017b),,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
178,HCMV,MERLIN,UL56,L257F,,,,,"8.6,14",,,,,Antiviral Research 163 (2019) 91–117,,,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
179,HCMV,AD169,UL56,L257I,,,,,4.9,,,,,Antiviral Research 163 (2019) 91–118,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
180,HCMV,MERLIN,UL56,K258E,,,,,14,,,,,Antiviral Research 163 (2019) 91–119,,,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
181,HCMV,AD169,UL56,F261C,,,,,4.4,,,,,Antiviral Research 163 (2019) 91–120,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
182,HCMV,AD169,UL56,F261L,,,,,2.8,,,,,Antiviral Research 163 (2019) 91–121,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
183,HCMV,AD169,UL56,Y321C,,,,,4.6,,,,,Antiviral Research 163 (2019) 91–122,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
184,HCMV,AD169,UL56,C325F,,,,,3000,,,,,Antiviral Research 163 (2019) 91–123,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
185,HCMV,AD169,UL56,C325R,,,,,3000,,,,,Antiviral Research 163 (2019) 91–124,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
186,HCMV,AD169,UL56,C325Y,,,,,3000,,,,,Antiviral Research 163 (2019) 91–125,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
187,HCMV,MERLIN,UL56,C325W,,,,,9000,,,,,Antiviral Research 163 (2019) 91–126,New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir,https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf,https://doi.org/10.1128/AAC.00922-18,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
188,HCMV,MERLIN,UL56,L328V,,,,,1.9,,,,,Antiviral Research 163 (2019) 91–127,,,,SEAP,in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
189,HCMV,AD169,UL56,M329T,,,,,4.4,,,,,Antiviral Research 163 (2019) 91–128,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
190,HCMV,AD169,UL56,A365S,,,,,2,,,,,Antiviral Research 163 (2019) 91–129,"New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir",https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf,"https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
191,HCMV,MERLIN,UL56,N368D,,,,,2,,,,,Antiviral Research 163 (2019) 91–130,,,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
192,HCMV,AD169,UL56,V231L,,,,,5,,,,,Antiviral Research 163 (2019) 91–131,Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure,https://aac.asm.org/content/aac/58/1/610.full.pdf,,"Recombinant BAC, fluorescence reduction assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
192,HCMV,AD169,UL56,L241P,,,,,218,,,,,Antiviral Research 163 (2019) 91–131,Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure,https://aac.asm.org/content/aac/58/1/610.full.pdf,,"Recombinant BAC, fluorescence reduction assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
192,HCMV,AD169,UL56,V236M,,,,,45,,,,,Antiviral Research 163 (2019) 91–131,Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure,https://aac.asm.org/content/aac/58/1/610.full.pdf,,"Recombinant BAC, fluorescence reduction assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
192,HCMV,AD169,UL56,R369G,,,,,44,,,,,Antiviral Research 163 (2019) 91–131,Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure,https://aac.asm.org/content/aac/58/1/610.full.pdf,,"Recombinant BAC, fluorescence reduction assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
193,HCMV,AD169,UL56,R369M,,,,,13,,,,,Antiviral Research 163 (2019) 91–132,Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure,https://aac.asm.org/content/aac/58/1/610.full.pdf,,"Recombinant BAC, fluorescence reduction assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
194,HCMV,AD169,UL56,R369S,,,,,48,,,,,Antiviral Research 163 (2019) 91–133,Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure,https://aac.asm.org/content/aac/58/1/610.full.pdf,,"Recombinant BAC, fluorescence reduction assay",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
195,HCMV,AD169,UL56,C25F,,,,,46,,,,,Antiviral Research 163 (2019) 91–134,"New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir",https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf,"https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP",in vitro,strong,Tested,UL56,V231L,17/11/2019,OJCharles,,,,,,,,,
196,HCMV,AD169,UL56,T244K,,,,,8.2,,,,,Antiviral Research 163 (2019) 91–135,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,"Recombinant BAC, SEAP",in vitro,strong,Tested,UL56,F261L,17/11/2019,OJCharles,,,,,,,,,
197,HCMV,AD169,UL56,E237D,,,,,104,,,,,Antiviral Research 163 (2019) 91–136,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,"Recombinant BAC, SEAP",in vitro,strong,Tested,UL56,"T244K, F261L",17/11/2019,OJCharles,,,,,,,,,
198,HCMV,AD169,UL56,V236L,,,,,260,,,,,Antiviral Research 163 (2019) 91–137,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,"Recombinant BAC, SEAP",in vitro,strong,Tested,UL56,L257I,17/11/2019,OJCharles,,,,,,,,,
199,HCMV,AD169,UL56,V236M,,,,,3000,,,,,Antiviral Research 163 (2019) 91–138,Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance,https://aac.asm.org/content/aac/59/10/6588.full.pdf,,"Recombinant BAC, SEAP",in vitro,strong,Tested,UL56,"L257I, M329T",17/11/2019,OJCharles,,,,,,,,,
200,HCMV,AD169,UL56,S229F,,,,,54,,,,,Antiviral Research 163 (2019) 91–139,A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance,https://www.sciencedirect.com/science/article/pii/S0166354217306393,https://doi.org/10.1016/j.antiviral.2017.10.019,"Recombinant BAC, SEAP",in vitro,strong,Tested,UL56,"L254F, L257I",17/11/2019,OJCharles,,,,,,,,,
201,HCMV,MERLIN,UL89,N320H,,,,,1.8,,,,,Antiviral Research 163 (2019) 91–135,Chou (2017a),,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
202,HCMV,MERLIN,UL89,N329S,,,,,2,,,,,Antiviral Research 163 (2019) 91–136,Chou (2017a),,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
203,HCMV,MERLIN,UL89,D344E,,,,,1.7,,,,,Antiviral Research 163 (2019) 91–137,Chou (2017a),,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
204,HCMV,MERLIN,UL89,T350M,,,,,2.8,,,,,Antiviral Research 163 (2019) 91–135,Chou (2017a),,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
205,HCMV,MERLIN,UL56,E237D,,,,,34,,,,,Antiviral Research 163 (2019) 91–137,Chou (2017b),,,"Recombinant BAC, SEAP",in vitro,strong,Tested,UL89,D344E,17/11/2019,OJCharles,,,,,,,,,
206,HCMV,MERLIN,UL56,F261L,,,,,4.8,,,,,Antiviral Research 163 (2019) 91–138,Chou (2017b),,,"Recombinant BAC, SEAP",in vitro,strong,Tested,UL89,D344E,17/11/2019,OJCharles,,,,,,,,,
207,HCMV,MERLIN,UL56,M329T,,,,,8,,,,,Antiviral Research 163 (2019) 91–139,Chou (2017b),,,"Recombinant BAC, SEAP",in vitro,strong,Tested,UL89,D344E,17/11/2019,OJCharles,,,,,,,,,
208,HCMV,MERLIN,UL56,Q204R,,,,,2.5,,,,,Antiviral Research 163 (2019) 91–136,Chou (2017b),,,"Recombinant BAC, SEAP",in vitro,strong,Tested,UL89,D344E,17/11/2019,OJCharles,,,,,,,,,
209,HCMV,MERLIN,UL51,P91S,,,,,2.1,,,,,Antiviral Research 163 (2019) 91–136,,,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
210,HCMV,MERLIN,UL51,P91S,,,,,6.3,,,,,Antiviral Research 163 (2019) 91–136,,,,"Recombinant BAC, SEAP",in vitro,strong,Tested,UL56,S229F,17/11/2019,OJCharles,,,,,,,,,
211,HCMV,MERLIN,UL51,P91S,,,,,28,,,,,Antiviral Research 163 (2019) 91–136,,,,"Recombinant BAC, SEAP",in vitro,strong,Tested,UL56,V236M,17/11/2019,OJCharles,,,,,,,,,
212,HCMV,MERLIN,UL51,P91S,,,,,126,,,,,Antiviral Research 163 (2019) 91–136,,,,"Recombinant BAC, SEAP",in vitro,strong,Tested,UL56,R369M,17/11/2019,OJCharles,,,,,,,,,
213,HCMV,MERLIN,UL51,P91S,,,,,290,,,,,Antiviral Research 163 (2019) 91–136,,,,"Recombinant BAC, SEAP",in vitro,strong,Tested,UL56,"S229F, L254F, L257I",17/11/2019,OJCharles,,,,,,,,,
214,HCMV,MERLIN,UL51,P91S,,,,,4,,,,,Antiviral Research 163 (2019) 91–136,,,,"Recombinant BAC, SEAP",in vitro,strong,Tested,UL89,D344E,17/11/2019,OJCharles,,,,,,,,,
215,HCMV,MERLIN,UL97,L337M,1,,,,,,,3.4,,Antiviral Research 163 (2019) 91–136,,,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
216,HCMV,MERLIN,UL97,F342S,7.8,17,,,,,,18,,Antiviral Research 163 (2019) 91–136,Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance,https://aac.asm.org/content/aac/57/7/3375.full.pdf,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
217,HCMV,MERLIN,UL97,V353A,1,,,,,,,10,,Antiviral Research 163 (2019) 91–136,Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance,https://academic.oup.com/jid/article/196/1/91/844651,https://doi.org/10.1086/518514,"Marker Transfer, PRA",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
218,HCMV,AD169,UL97,K355del,16,23,,,,,,304,,Antiviral Research 163 (2019) 91–136,Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance,https://aac.asm.org/content/aac/57/7/3375.full.pdf,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
219,HCMV,MERLIN,UL97,V356G,5.5,7,,,,,,108,,Antiviral Research 163 (2019) 91–136,Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance,https://aac.asm.org/content/aac/57/7/3375.full.pdf,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
220,HCMV,MERLIN,UL97,L397R,1.6,,,,,,,>200,,Antiviral Research 163 (2019) 91–136,,,,"Marker Transfer, PRA",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
221,HCMV,MERLIN,UL97,T409M,0.9,,,,,,,81,,Antiviral Research 163 (2019) 91–136,,,,"Recombinant BAC, Marker transfer",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
222,HCMV,MERLIN,UL97,H411L,0.7,,,,,,,69,,Antiviral Research 163 (2019) 91–136,,,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
223,HCMV,MERLIN,UL97,H411N,1,,,,,,,9,,Antiviral Research 163 (2019) 91–136,,,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
224,HCMV,MERLIN,UL97,H411Y,0.5,,,,,,,12,,Antiviral Research 163 (2019) 91–136,,,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
225,HCMV,MERLIN,UL97,D456N,12,,,,,,,278,,Antiviral Research 163 (2019) 91–136,,,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
226,HCMV,MERLIN,UL97,V466G,11,17,,,,,,321,,Antiviral Research 163 (2019) 91–136,Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance,https://aac.asm.org/content/aac/57/7/3375.full.pdf,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
227,HCMV,MERLIN,UL97,C480R,9,,,,,,,243,,Antiviral Research 163 (2019) 91–136,,,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
228,HCMV,#####,UL97,P521L,17,20,,,,,,445,,Antiviral Research 163 (2019) 91–136,Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance,https://aac.asm.org/content/aac/57/7/3375.full.pdf,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
229,HCMV,MERLIN,UL97,Y617del,10,,,,,,,372,,Antiviral Research 163 (2019) 91–136,,,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
230,HCMV,MERLIN,UL97,V353A,1,,,,,,,227,,Antiviral Research 163 (2019) 91–136,,,,"Recombinant BAC, SEAP",in vitro,strong,Tested,UL97,H411L,17/11/2019,OJCharles,,,,,,,,,
231,HCMV,MERLIN,UL97,V353A,0.7,,,,,,,164,,Antiviral Research 163 (2019) 91–136,,,,"Recombinant BAC, SEAP",in vitro,strong,Tested,UL97,H411Y,17/11/2019,OJCharles,,,,,,,,,
232,HCMV,MERLIN,AD169,E22*,,,,,,,,2,,Antiviral Research 163 (2019) 91–136,Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir,https://aac.asm.org/content/53/1/81,DOI: 10.1128/AAC.01177-08,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
233,HCMV,MERLIN,UL27,W153R,,,,,,,,1.7,,Antiviral Research 163 (2019) 91–136,Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir,https://aac.asm.org/content/53/1/81,DOI: 10.1128/AAC.01177-08,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
234,HCMV,MERLIN,UL27,L193F,,,,,,,,2.6,,Antiviral Research 163 (2019) 91–136,Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir,https://aac.asm.org/content/53/1/81,DOI: 10.1128/AAC.01177-08,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
235,HCMV,MERLIN,UL27,C218del,,,,,,,,2.5,,Antiviral Research 163 (2019) 91–136,Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir,https://aac.asm.org/content/53/1/81,DOI: 10.1128/AAC.01177-08,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
236,HCMV,MERLIN,UL27,R233S,,,,,,,,"1.8,4.8",,Antiviral Research 163 (2019) 91–136,,,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
237,HCMV,MERLIN,UL27,A269T,,,,,,,,2,,Antiviral Research 163 (2019) 91–136,Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir,https://aac.asm.org/content/53/1/81,DOI: 10.1128/AAC.01177-08,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
238,HCMV,MERLIN,UL27,del301-311,,,,,,,,3.1,,Antiviral Research 163 (2019) 91–136,Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir,https://aac.asm.org/content/53/1/81,DOI: 10.1128/AAC.01177-08,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
239,HCMV,MERLIN,UL27,L335P,,,,,,,,23,,Antiviral Research 163 (2019) 91–136,,,,"Recombinant BAC, #####",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
240,HCMV,MERLIN,UL27,V353E,,,,,,,,2.1,,Antiviral Research 163 (2019) 91–136,Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir,https://aac.asm.org/content/53/1/81,DOI: 10.1128/AAC.01177-08,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
241,HCMV,MERLIN,UL27,W362R,,,,,,,,1.9,,Antiviral Research 163 (2019) 91–136,Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir,https://aac.asm.org/content/53/1/81,DOI: 10.1128/AAC.01177-08,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
242,HCMV,MERLIN,UL27,W362*,,,,,,,,2.2,,Antiviral Research 163 (2019) 91–136,,,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
243,HCMV,MERLIN,UL27,L426F,,,,,,,,2.2,,Antiviral Research 163 (2019) 91–136,,,,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,17/11/2019,OJCharles,,,,,,,,,
244,HCMV,MERLIN,UL27,A406V,,,,,,,,3.5,,Antiviral Research 163 (2019) 91–136,,,,#####,in vitro,strong,Tested,UL27,C415*,17/11/2019,OJCharles,,,,,,,,,
245,HCMV,MERLIN,UL27,R233S,,,,,,,,7.2,,Antiviral Research 163 (2019) 91–136,,,,"Recombinant Virus, SEAP",in vitro,strong,Tested,UL97,S337M,17/11/2019,OJCharles,,,,,,,,,
246,HCMV,MERLIN,UL27,R233S,,,,,,,,27,,Antiviral Research 163 (2019) 91–136,,,,"Recombinant Virus, SEAP",in vitro,strong,Tested,UL97,S337M,17/11/2019,OJCharles,,,,,,,,,
247,HCMV,MERLIN,UL54,G841G,R,,R,,,,,R,,https://doi.org/10.1016/j.antiviral.2019.104647,,,,,,,Hyp,,,19/11/2019,OJCharles,,U,,,,,,,
248,HCMV,MERLIN,UL54,K513N,R,,R,,,,,R,,https://doi.org/10.1016/j.antiviral.2019.104647,,,,,,,Hyp,,,19/11/2019,OJCharles,,U,,,,,,,
249,HCMV,MERLIN,UL97,H411H,R,,R,,,,,R,,https://doi.org/10.1016/j.antiviral.2019.104647,,,,,,,Hyp,,,19/11/2019,OJCharles,,U,,,,,,,
250,HCMV,MERLIN,UL97,C670Y,R,,,,,,,,,,Management of Ganciclovir Resistant Cytomegalovirus Retinitis in a Solid Organ Transplant Recipient: A Review of Current Evidence and Treatment Approaches,https://www.tandfonline.com/doi/full/10.1080/09273948.2019.1645188,https://doi.org/10.1080/09273948.2019.1645188,Sequence Alignment,Anecdotal,weak,Hyp,,,19/11/2019,OJCharles,,,,,,,,,
251,HCMV,AD169,UL97,F342Y,6,,,,,,,4.5,,,Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection,https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub,https://doi.org/10.1016/j.antiviral.2019.104616,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,21/11/2019,OJCharles,,,,,,,,,
,HCMV,AD169,UL97,C592G,3,,,,,,,,,,Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection,https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub,https://doi.org/10.1016/j.antiviral.2019.104616,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,,,,,,,,,,,
,HCMV,AD169,UL97,H411Y,,,,,,,,18,,,Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection,https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub,https://doi.org/10.1016/j.antiviral.2019.104616,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,,,,,,,,,,,
252,HCMV,AD169,UL97,T409M,,,,,,,,90,,,Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection,https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub,https://doi.org/10.1016/j.antiviral.2019.104616,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,21/11/2019,OJCharles,,,,,,,,,
253,HCMV,AD169,UL97,K359E,3.8,,,,,,,1.2,,,Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection,https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub,https://doi.org/10.1016/j.antiviral.2019.104616,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,21/11/2019,OJCharles,,,,,,,,,
254,HCMV,AD169,UL97,K359Q,3.7,,,,,,,1.3,,,Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection,https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub,https://doi.org/10.1016/j.antiviral.2019.104616,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,21/11/2019,OJCharles,,,,,,,,,
255,HCMV,AD169,UL97,F342Y,5.9,,,,,,,56,,,Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection,https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub,https://doi.org/10.1016/j.antiviral.2019.104616,"Recombinant BAC, SEAP",in vitro,strong,Tested,UL97,H411Y,21/11/2019,OJCharles,,,,,,,,,
257,HCMV,MERLIN,UL54,S290R,R,,R,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,,Reported,weak,Tested,,,21/11/2019,OJCharles,,,,,,,,,
258,HCMV,MERLIN,UL54,E303D,R,R,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,,Reported,weak,Tested,,,21/11/2019,OJCharles,,,,,,,,,
259,HCMV,MERLIN,UL54,E303G,R,R,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,,Reported,weak,Tested,,,21/11/2019,OJCharles,,,,,,,,,
260,HCMV,MERLIN,UL54,D413Y,R,R,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,,Reported,weak,Tested,,,21/11/2019,OJCharles,,,,,,,,,
261,HCMV,MERLIN,UL54,K488R,R,R,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,,Reported,weak,Tested,,,21/11/2019,OJCharles,,,,,,,,,
262,HCMV,MERLIN,UL54,E951D,R,,R,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,,Reported,weak,Tested,,,21/11/2019,OJCharles,,,,,,,,,
263,HCMV,MERLIN,UL54,L516W,R,R,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,,Reported,weak,Tested,,,21/11/2019,OJCharles,,,,,,,,,
264,HCMV,MERLIN,UL54,V715A,,,R,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,,Reported,weak,Tested,,,21/11/2019,OJCharles,,,,,,,,,
265,HCMV,MERLIN,UL97,A674T,<2,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,,Reported,weak,Tested,,,21/11/2019,OJCharles,,,,,,,,,
266,HCMV,MERLIN,UL97,L634Q,<2,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,,Reported,weak,Tested,,,21/11/2019,OJCharles,,,,,,,,,
267,HCMV,MERLIN,UL97,Y617H,<2,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,,Reported,weak,Tested,,,21/11/2019,OJCharles,,,,,,,,,
268,HCMV,MERLIN,UL97,M615V,<2,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,,Reported,weak,Tested,,,21/11/2019,OJCharles,,,,,,,,,
269,HCMV,MERLIN,UL97,D605E,<2,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,,Reported,weak,Tested,,,21/11/2019,OJCharles,,,,,,,,,
270,HCMV,MERLIN,UL97,T601M,<2,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,,Reported,weak,Tested,,,21/11/2019,OJCharles,,,,,,,,,
271,HCMV,MERLIN,UL97,L600I,<2,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,,Reported,weak,Tested,,,21/11/2019,OJCharles,,,,,,,,,
272,HCMV,MERLIN,UL97,K599E,<2,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,,Reported,weak,Tested,,,21/11/2019,OJCharles,,,,,,,,,
273,HCMV,MERLIN,UL97,K599R,<2,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,,Reported,weak,Tested,,,21/11/2019,OJCharles,,,,,,,,,
274,HCMV,MERLIN,UL97,K957D,<2,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,,Reported,weak,Tested,,,21/11/2019,OJCharles,,,,,,,,,
275,HCMV,MERLIN,UL97,E596D,<2,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,,Reported,weak,Tested,,,21/11/2019,OJCharles,,,,,,,,,
276,HCMV,MERLIN,UL97,A591V,2-5,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,,Reported,weak,Tested,,,21/11/2019,OJCharles,,,,,,,,,
277,HCMV,MERLIN,UL97,596del,2-5,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,,Reported,weak,Tested,,,21/11/2019,OJCharles,,,,,,,,,
278,HCMV,MERLIN,UL97,C603S,2-5,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,,Reported,weak,Tested,,,21/11/2019,OJCharles,,,,,,,,,
279,HCMV,MERLIN,UL97,596del,2-5,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,,Reported,weak,Tested,,,21/11/2019,OJCharles,,,,,,,,,
280,HCMV,MERLIN,UL97,del600-602,2-5,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,,Reported,weak,Tested,,,21/11/2019,OJCharles,,,,,,,,,
281,HCMV,MERLIN,UL97,C607F,2-5,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,,Reported,weak,Tested,,,21/11/2019,OJCharles,,,,,,,,,
282,HCMV,MERLIN,UL97,K355M,5-15,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,,Reported,weak,Tested,,,21/11/2019,OJCharles,,,,,,,,,
283,HCMV,MERLIN,UL97,V466G,5-15,,,,,,,,,,"The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation",https://www.ncbi.nlm.nih.gov/pubmed/29596116,doi: 10.1097/TP.0000000000002191.,,Reported,weak,Tested,,,21/11/2019,OJCharles,,,,,,,,,
,,Suscept,UL97,A594V,R,,,,,,,,,https://doi.org/10.1080/14656566.2019.1637418,Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.,https://www.ncbi.nlm.nih.gov/pubmed/14739146?dopt=Abstract,DOI: 10.1093/jac/dkh065,Sequence Alignment,Anecdotal,weak,hyp,,,,,,,,,,,,,
,,Suscept,UL54,P522S,R,R,,,,,,,,https://doi.org/10.1080/14656566.2019.1637418,Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.,https://www.ncbi.nlm.nih.gov/pubmed/14739146?dopt=Abstract,DOI: 10.1093/jac/dkh065,Sequence Alignment,Anecdotal,weak,hyp,,,,,,,,,,,,,
,,AD169,UL56,V236M,1,1.9,1.1,,46,,,,,https://doi.org/10.1080/14656566.2019.1637418,"Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)",https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract,. doi: 10.1093/infdis/jiv352,"Marker Transfer, GFP-fluorescence
reduction assay",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL56,D414N,0.4,0.3,0.4,,0.9,,,,,https://doi.org/10.1080/14656566.2019.1637418,"Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)",https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract,. doi: 10.1093/infdis/jiv352,"Marker Transfer, GFP-fluorescence
reduction assay",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL56,S227I,0.4,0.3,0.4,,0.2,,,,,https://doi.org/10.1080/14656566.2019.1637418,"Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)",https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract,. doi: 10.1093/infdis/jiv352,"Marker Transfer, GFP-fluorescence
reduction assay",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL56,R410G,0.8,0.2,0.4,,0.4,,,,,https://doi.org/10.1080/14656566.2019.1637418,"Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)",https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract,. doi: 10.1093/infdis/jiv352,"Marker Transfer, GFP-fluorescence
reduction assay",in vitro,strong,Tested,,,,,,,,,,,,,
284,HCMV,MERLIN,UL56,E237G,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,U,,,,,,,
285,HCMV,MERLIN,Ul56,M31I,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
286,HCMV,MERLIN,Ul56,M31V,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
287,HCMV,MERLIN,Ul56,F41L,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
288,HCMV,MERLIN,Ul56,L26P,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
289,HCMV,MERLIN,Ul56,I48M,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
290,HCMV,MERLIN,Ul56,A103V,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
291,HCMV,MERLIN,Ul56,E141*,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
292,HCMV,MERLIN,Ul56,N148D,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
293,HCMV,MERLIN,Ul56,E157G,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
294,HCMV,MERLIN,Ul56,Q182K,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
295,HCMV,MERLIN,Ul56,Q213R,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
296,HCMV,MERLIN,Ul56,S255L,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
297,HCMV,MERLIN,Ul56,S269G,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
298,HCMV,MERLIN,Ul56,E276G,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
299,HCMV,MERLIN,Ul56,I313V,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
300,HCMV,MERLIN,Ul56,C325W,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
301,HCMV,MERLIN,Ul56,S378N,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
302,HCMV,MERLIN,Ul56,S445N,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
303,HCMV,MERLIN,Ul56,E485G,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
304,HCMV,MERLIN,Ul56,I535V,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
305,HCMV,MERLIN,Ul56,E542DEL,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
306,HCMV,MERLIN,Ul56,Y575C,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
307,HCMV,MERLIN,Ul56,M641T,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
308,HCMV,MERLIN,Ul56,L658S,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
309,HCMV,MERLIN,Ul56,Y667H,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
310,HCMV,MERLIN,Ul56,S705F,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
311,HCMV,MERLIN,Ul56,V706A,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
312,HCMV,MERLIN,Ul56,L750P,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
313,HCMV,MERLIN,Ul56,Y757H,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
314,HCMV,MERLIN,Ul56,T775I,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
315,HCMV,MERLIN,Ul56,R816W,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
316,HCMV,MERLIN,Ul56,P846L,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
317,HCMV,MERLIN,UL89,K41E,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
318,HCMV,MERLIN,UL89,N74S,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
319,HCMV,MERLIN,UL89,S102F,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
320,HCMV,MERLIN,UL89,F124L,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
321,HCMV,MERLIN,UL89,T132A,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
322,HCMV,MERLIN,UL89,V146I,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
323,HCMV,MERLIN,UL89,P176S,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
324,HCMV,MERLIN,UL89,H243R,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
325,HCMV,MERLIN,UL89,H246R,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
326,HCMV,MERLIN,UL89,D309G,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
327,HCMV,MERLIN,UL89,L323P,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
328,HCMV,MERLIN,UL89,T331A,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
329,HCMV,MERLIN,UL89,S373G,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
330,HCMV,MERLIN,UL89,M406V,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
331,HCMV,MERLIN,UL89,N426D,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
332,HCMV,MERLIN,UL89,L458P,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
333,HCMV,MERLIN,UL89,S521G,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
334,HCMV,MERLIN,UL89,L522P,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
335,HCMV,MERLIN,UL89,A532T,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
336,HCMV,MERLIN,UL89,I572V,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
337,HCMV,MERLIN,UL89,Q625*,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
338,HCMV,MERLIN,UL89,T637A,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
339,HCMV,MERLIN,UL89,V656A,,,,,R,,,,,,In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products,https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub,https://doi.org/10.1080/14656566.2019.1637418,Sequence Alignment,Phase 3 trial anecdotal evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
,,AD169,UL54,V787A,2.9,1.3,5.25,,,,,,,,Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis,https://academic.oup.com/jid/article/220/8/1302/5519111,https://doi.org/10.1093/infdis/jiz298,"Recombinant BAC, GLuc reporter–based assay",in vitro,strong,Tested,,,,,,,,,,,,,
340,HCMV,AD169,UL54,V787E,8.5,2.9,3.4,,,,,,,,Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis,https://academic.oup.com/jid/article/220/8/1302/5519111,https://doi.org/10.1093/infdis/jiz298,"Recombinant BAC, GLuc reporter–based assay",in vitro,strong,Tested,,,21/11/2019,OJCharles,,,,,,,,,
341,HCMV,AD169,UL54,V787K,3.2,1.8,9.4,,,,,,,,Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis,https://academic.oup.com/jid/article/220/8/1302/5519111,https://doi.org/10.1093/infdis/jiz298,"Recombinant BAC, GLuc reporter–based assay",in vitro,strong,Tested,,,21/11/2019,OJCharles,,,,,,,,,
342,HCMV,MERLIN,UL54,L501F,,R,,,,,,,,,Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands,https://academic.oup.com/jac/article/74/8/2370/5489804,https://doi.org/10.1093/jac/dkz196,Sequence Alignment,anecdotal clinical evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
343,HCMV,MERLIN,UL54,A505T,,R,,,,,,,,,Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands,https://academic.oup.com/jac/article/74/8/2370/5489804,https://doi.org/10.1093/jac/dkz196,Sequence Alignment,anecdotal clinical evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
344,HCMV,MERLIN,UL97,H469Y,R,,,,,,,,,,Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands,https://academic.oup.com/jac/article/74/8/2370/5489804,https://doi.org/10.1093/jac/dkz196,Sequence Alignment,anecdotal clinical evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
345,HCMV,MERLIN,UL97,A590V ,R,,,,,,,,,,Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands,https://academic.oup.com/jac/article/74/8/2370/5489804,https://doi.org/10.1093/jac/dkz196,Sequence Alignment,anecdotal clinical evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
346,HCMV,MERLIN,UL54,D1129N,R,,,,,,,,,,Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands,https://academic.oup.com/jac/article/74/8/2370/5489804,https://doi.org/10.1093/jac/dkz196,Sequence Alignment,anecdotal clinical evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
347,HCMV,MERLIN,UL54,V321I ,R,,,,,,,,,,Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands,https://academic.oup.com/jac/article/74/8/2370/5489804,https://doi.org/10.1093/jac/dkz196,Sequence Alignment,anecdotal clinical evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
348,HCMV,MERLIN,UL97,L609F ,R,R,,,,,,,,,Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands,https://academic.oup.com/jac/article/74/8/2370/5489804,https://doi.org/10.1093/jac/dkz196,Sequence Alignment,anecdotal clinical evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
349,HCMV,MERLIN,UL54,R1030C ,R,,,,,,,,,,Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands,https://academic.oup.com/jac/article/74/8/2370/5489804,https://doi.org/10.1093/jac/dkz196,Sequence Alignment,anecdotal clinical evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
350,HCMV,MERLIN,UL54,G1031A,R,,,,,,,,,,Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands,https://academic.oup.com/jac/article/74/8/2370/5489804,https://doi.org/10.1093/jac/dkz196,Sequence Alignment,anecdotal clinical evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
351,HCMV,MERLIN,UL54,L394F ,R,,,,,,,,,,Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands,https://academic.oup.com/jac/article/74/8/2370/5489804,https://doi.org/10.1093/jac/dkz196,Sequence Alignment,anecdotal clinical evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
352,HCMV,MERLIN,UL54,E877K,R,,,,,,,,,,Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands,https://academic.oup.com/jac/article/74/8/2370/5489804,https://doi.org/10.1093/jac/dkz196,Sequence Alignment,anecdotal clinical evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
353,HCMV,MERLIN,UL97,L609F,R,R,,,,,,,,,Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands,https://academic.oup.com/jac/article/74/8/2370/5489804,https://doi.org/10.1093/jac/dkz196,Sequence Alignment,anecdotal clinical evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
354,HCMV,MERLIN,UL54,T892A,R,,,,,,,,,,Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands,https://academic.oup.com/jac/article/74/8/2370/5489804,https://doi.org/10.1093/jac/dkz196,Sequence Alignment,anecdotal clinical evidence,weak,Hypothesised,,,21/11/2019,OJCharles,,,,,,,,,
355,HCMV,MERLIN,UL97,M460I,7.8,,,,,,,,12,,Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility,https://aac.asm.org/content/55/1/382,https://dx.doi.org/10.1128%2FAAC.01259-10,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,22/11/2019,OJCharles,,,,,,,,,
356,HCMV,MERLIN,UL97,M460T,9.3,,,,,,,,10,,Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility,https://aac.asm.org/content/55/1/382,https://dx.doi.org/10.1128%2FAAC.01259-10,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,22/11/2019,OJCharles,,,,,,,,,
357,HCMV,MERLIN,UL97,M460V,8.3,,,,,,,,4,,Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility,https://aac.asm.org/content/55/1/382,https://dx.doi.org/10.1128%2FAAC.01259-10,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,22/11/2019,OJCharles,,,,,,,,,
358,HCMV,MERLIN,UL97,H520Q,7.8,,,,,,,,20,,Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility,https://aac.asm.org/content/55/1/382,https://dx.doi.org/10.1128%2FAAC.01259-10,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,22/11/2019,OJCharles,,,,,,,,,
359,HCMV,MERLIN,UL97,C592G,3,,,,,,,,3.3,,Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility,https://aac.asm.org/content/55/1/382,https://dx.doi.org/10.1128%2FAAC.01259-10,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,22/11/2019,OJCharles,,,,,,,,,
360,HCMV,MERLIN,UL97,A594V,8.6,,,,,,,,4.5,,Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility,https://aac.asm.org/content/55/1/382,https://dx.doi.org/10.1128%2FAAC.01259-10,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,22/11/2019,OJCharles,,,,,,,,,
361,HCMV,MERLIN,UL97,L595S,8.5,,,,,,,,1.3,,Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility,https://aac.asm.org/content/55/1/382,https://dx.doi.org/10.1128%2FAAC.01259-10,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,22/11/2019,OJCharles,,,,,,,,,
362,HCMV,MERLIN,UL97,C603R,8.3,,,,,,,,8.4,,Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility,https://aac.asm.org/content/55/1/382,https://dx.doi.org/10.1128%2FAAC.01259-10,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,22/11/2019,OJCharles,,,,,,,,,
363,HCMV,MERLIN,UL97,C603S,1.9,,,,,,,,2.8,,Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility,https://aac.asm.org/content/55/1/382,https://dx.doi.org/10.1128%2FAAC.01259-10,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,22/11/2019,OJCharles,,,,,,,,,
364,HCMV,MERLIN,UL97,C603W,7.9,,,,,,,,4.6,,Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility,https://aac.asm.org/content/55/1/382,https://dx.doi.org/10.1128%2FAAC.01259-10,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,22/11/2019,OJCharles,,,,,,,,,
365,HCMV,AD169,UL54,D515Y,3.2,2.6,,,,,,,,,Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection,https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135,https://doi.org/10.1111/ajt.15135,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,22/11/2019,OJCharles,,,,,,,,,
366,HCMV,AD169,UL54,L516P,4.4,5.9,,,,,,,,,Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection,https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135,https://doi.org/10.1111/ajt.15135,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,22/11/2019,OJCharles,,,,,,,,,
,,AD169,UL54,del981-2,7,3.2,2.7,,,,,,,,Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection,https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135,https://doi.org/10.1111/ajt.15135,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,,,,,,,,,,,
367,HCMV,MERLIN,UL54,L415N,,,R,,,,,,,,Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial,https://academic.oup.com/cid/article/68/4/632/5049442,https://doi.org/10.1093/cid/ciy549,Sequence Alignment,anecdotal clinical evidence,weak,Hypothesised,,,22/11/2019,OJCharles,,,,,,,,,
368,HCMV,MERLIN,UL54,S734P,,,R,,,,,,,,Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial,https://academic.oup.com/cid/article/68/4/632/5049442,https://doi.org/10.1093/cid/ciy549,Sequence Alignment,anecdotal clinical evidence,weak,Hypothesised,,,22/11/2019,OJCharles,,,,,,,,,
369,HCMV,AD169,UL54,A543P,4.7,16,0.6,,,,,,,,"New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir",https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf,"https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP",in vitro,strong,,,,22/11/2019,OJCharles,,,,,,,,,
,HCMV,AD169,UL54,S290R,1.7,1.4,2.3,,,,,,,,Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/,doi: 10.1016/j.antiviral.2016.12.003,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,K426E,1.1,1,1.1,,,,,,,,Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/,doi: 10.1016/j.antiviral.2016.12.003,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,N495K,1.3,1,2.6,,,,,,,,Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/,doi: 10.1016/j.antiviral.2016.12.003,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,N495K,1.7,1.2,3.5,,,,,,,,Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/,doi: 10.1016/j.antiviral.2016.12.003,"Recombinant BAC, SEAP",in vitro,strong,Tested,UL54,Q738R,,,,,,,,,,,
,,AD169,UL54,T552N,1.8,1,2.5,,,,,,,,Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/,doi: 10.1016/j.antiviral.2016.12.003,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,Q783R,1.8,0.9,1.7,,,,,,,,Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/,doi: 10.1016/j.antiviral.2016.12.003,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,V798A,1.5,1.1,1.7,,,,,,,,Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/,doi: 10.1016/j.antiviral.2016.12.003,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,,,,,,,,,,,
,,AD169,UL54,E951D,1.8,1.2,3.9,,,,,,,,Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/,doi: 10.1016/j.antiviral.2016.12.003,"Recombinant BAC, SEAP",in vitro,strong,Tested,,,,,,,,,,,,,
,,TOWNE,UL54,T419M,1,,8,,,,,,,,Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase,https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub,https://doi.org/10.1016/S1386-6532(02)00046-X,"Drug induced lab mutant, CMV antigen ELISA ",in vitro,strong,Tested,,,,,,,,,,,,,
,,TOWNE,UL54,Q578H,2,,10,,,,,,,,Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase,https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub,https://doi.org/10.1016/S1386-6532(02)00046-X,"Drug induced lab mutant, CMV antigen ELISA ",in vitro,strong,Tested,,,,,,,,,,,,,
,,TOWNE,UL54,L773V,2,,5,,,,,,,,Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase,https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub,https://doi.org/10.1016/S1386-6532(02)00046-X,"Drug induced lab mutant, CMV antigen ELISA ",in vitro,strong,Tested,,,,,,,,,,,,,
,,TOWNE,UL97,M460V,10,,1,,,,,,,,Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase,https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub,https://doi.org/10.1016/S1386-6532(02)00046-X,"Drug induced lab mutant, CMV antigen ELISA ",in vitro,strong,Tested,,,,,,,,,,,,,
not sure I trust this,HCMV,,UL97,T419M,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,22/11/2019,OJCharles,,,,,,,,,
,,,UL97,N68D,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL97,L126Q,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL97,I244V,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL97,D329H,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL97,A427V,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL97,Q449K,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL97,V466M,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL97,H469Y,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL97,A478V,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL97,N510S,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL97,M550I,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL97,A582V,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL97,H587Y,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL97,A588V,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL97,A591V,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL97,N597D,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL97,K599R,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL97,L600I,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL97,D605E,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL97,M615V,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL97,Y617H,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL97,G623S,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL97,L634Q,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL97,T659I,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL97,V665I,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL97,A674T,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL97,Q19E,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL97,T95S,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL97,S108N,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL97,R112C,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL97,R137C,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL97,E227D,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL97,A582T,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL54,D515G,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL54,P522L,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL54,A692S,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,,UL54,G971D,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Transfer to control strain,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,A15T,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,S24L,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,S32P,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,V95E,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,H142Y,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,G143S,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,I341T,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,N345S,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,G347D,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,V355A,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,S464F,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,A626V,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,P628L,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,G629S,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,A631G,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,S633F,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,M640R,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,S655L,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,S663N,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,F669L,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,S676G,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,G678S,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,VSNDNHGA681Del 8,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,N685S,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,A688V,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,T691A,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,A693T,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,S695T,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,Q697H,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,L737M,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,V759M,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,Q868R,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,D870H,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,V873L,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,G874R,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,S884Insert T,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,A885S,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,A885T,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,P887S,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,L890F,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,T892I,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,S897L,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,N898D,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,E899K,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,V927M,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,V953A,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,A1012V,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,L1020I,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,T1108A,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,N1116H,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,A1122T,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,G1133S,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,S1146N,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,N1147S,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,R1149T,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,G1151Del,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,P1153S,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,A1154P,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,K1156Del,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,P1162L,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL54,S1235T,S,,,,,,,,,,Antiviral Drug Resistance of Human Cytomegalovirus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/,doi: 10.1128/CMR.00009-10,Clinical isolate,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL97,C603W,1.1,0.9,1.5,,,,,,,,High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes,https://academic.oup.com/jid/article/176/1/69/901024,https://doi.org/10.1086/514041,Plaque reduction assay,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL97,H469Y,1.3,1.5,1.9,,,,,,,,High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes,https://academic.oup.com/jid/article/176/1/69/901024,https://doi.org/10.1086/514041,Plaque reduction assay,in vitro,strong,Tested,,,,,,,,,,,,,
,,Clinical Isolate,UL97,C603W,2,0.8,2,,,,,,,,High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes,https://academic.oup.com/jid/article/176/1/69/901024,https://doi.org/10.1086/514041,Plaque reduction assay,in vitro,strong,Tested,,,,,,,,,,,,,
